Large Molecule Research & Perspectives

  1. How AI Is Reshaping CRDMOs 5/27/2026

    Artificial intelligence is transforming CRDMOs by improving risk prediction, process efficiency, and decision-making, enabling more predictable, data-driven drug development and manufacturing across the lifecycle.

  2. Decoding The FDA's AMT Program Through Process Analytical Technology 5/27/2026

    Process analytical technology enables real-time monitoring and control in pharmaceutical manufacturing, supporting FDA advanced manufacturing initiatives to improve efficiency, product quality, and supply reliability.

  3. A Viral Testing Facility – Striving For Excellence 5/27/2026

    A GLP-certified viral testing facility ensures biologics safety through comprehensive detection and clearance services, supporting compliance and consistent production of high-quality therapeutics.

  4. Gene To GMP-Grade Clinical Supply In 9 Months 5/27/2026

    An integrated, platform-based approach enables rapid biologics development, cutting gene-to-GMP timelines to nine months through optimized processes, data-driven design, and streamlined scale-up.

  5. pDNA And mRNA Manufacturing In The Age Of Precision Therapies 5/27/2026

    CDMOs play a critical role in scaling pDNA and mRNA manufacturing, enabling precision therapies through flexible capacity, regulatory expertise, and high-quality, cost-efficient production solutions.

  6. Plasmid, mRNA, And Viral Vector Manufacturing 5/27/2026

    Scaling plasmid, mRNA, and viral vector production is key for gene therapies, requiring integrated processes, quality inputs, and advanced capabilities for consistent, reliable supply.

  7. Bispecific Antibodies: Engineering Complexity Into Simplicity 5/27/2026

    Bispecific antibodies deliver dual-target precision but require advanced design to balance stability, manufacturability, and performance for treating complex diseases beyond single-target biologics.

  8. Advancing mAb Manufacturing With Customer-Centric Solutions 5/27/2026

    Customer-centric innovations in monoclonal antibody manufacturing address cost, scalability, and regulatory challenges while improving yield, efficiency, and delivery of complex biologic therapies.

  9. Achieving Manufacturing Milestones Through Systematic Tech Transfer 5/27/2026

    A risk-based approach to tech transfer ensures consistent biologics manufacturing, enabling efficient scale-up, reduced risk, and reliable, right-first-time outcomes across production.

  10. Reducing Variability In Gene Expression: Bottlenecks And Solutions 5/26/2026

    Gene expression variability in biologics comes from random gene integration and cell heterogeneity; advanced engineering and targeted integration improve consistency, stability, and productivity.